Fig. 2.

Dosage regimen. Rituximab (RTX) and investigational drug (mycophenolate mofetil (MMF) or placebo) are administered in this trial. The date the first dose of RTX is administered is defined as day 1 and the date MMF administration is finished will be day 505. Calcineurin inhibitors (cyclosporine, tacrolimus) administered prior to registration for this clinical trial are administered in combination with the trial regimen and dosage at the time of registration until day 85 (however the dosage may be changed based on monitoring) and the dosage will be sequentially reduced every 28 days from day 86 onwards and discontinued approximately on day 169. MMF, mizoribine, azathioprine, cyclophosphamide, chlorambucil administered prior to the registration of this clinical trial, are discontinued on day 1. Prednisolone will be administered for treatment of relapse immediately prior to registration or during the observation period